Is Cellectis SA halal to invest in?

According to Musaffa's Shariah screening methodology, Cellectis SA (ALCLS.PA) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Cellectis SA a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Cellectis SA using these criteria to determine its compliance status.

Can Muslims buy shares of Cellectis SA?

Muslim investors may consider investing in Cellectis SA if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Cellectis SA classified as NOT HALAL?

Musaffa determines the Shariah status of Cellectis SA by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Cellectis SA updated?

The Shariah compliance status of Cellectis SA may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Cellectis SA become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Cellectis SA?

You can check the latest Shariah compliance status of Cellectis SA on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Cellectis SA ALCLS.PA

€3.61 €0.05 (1.29%) 1D

Last Updated: May 15, 12:00 AM·XPAR

ALCLS.PA Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: April 17, 2026

Report Source: 2025 Annual Report

Cellectis SA. Stock Analysis ALCLS.PA

France Health Care Micro Cap Report: 2025 Annual

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 229 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.

Key Statistics of Cellectis SA (ALCLS.PA)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€3.56€3.68

Today's Open

€3.56

Volume

29.42K

P/E Ratio (TTM)

52 Week Range

€1.23€4.84

Market Cap

228.55M

Avg. Volume

35.97K

Dividend Yield

Financial Metrics & Statements of Cellectis SA (ALCLS.PA)

FAQ's for Cellectis SA (ALCLS.PA)

According to Musaffa’s Shariah screening methodology, Cellectis SA (ALCLS.PA) is currently classified as NOT HALAL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.